FCGR2A and neoplasm: Studies have shown that targeting CD47 with anti-CD47 or a SIRPα fusion protein containing IgG1 Fc could exert dual effects, disrupting CD47-SIRPα interaction and promoting FcγR-mediated phagocytosis, which results in an enhanced clearance of tumor cells by macrophages and other APCs [35,36].